Fails 2 of 8 criteria. S4, compounding disclosure: The sermorelin and glutathione pages carry no statement that the product is compounded or that it is not FDA-approved. The tirzepatide and NAD+ pages carry the statement, but the pages selling sermorelin and glutathione do not. 1 more criterion also fails; see the table below.
At a glance
NavioMDTelehealth service
6/8criteria passed
Price
Tirzepatide $189 a month at lower doses, listed against a struck-through $299
Sells
compounded tirzepatide, brand Zepbound KwikPen, sermorelin, and 4 more
Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.
A telehealth service selling compounded tirzepatide at two dose-tier prices, brand Zepbound, sermorelin, NAD+ and glutathione injections, and hormone care for women. Its terms name The Pharmacy Hub as its only pharmacy, and its sermorelin page carries no compounding disclosure.
The evidence behind each disposition in the table above, where it appears, and its date.
S1PASSA licensed physician reviews each health history before a treatment is recommended, and the telehealth consent names Qualiphy as the partner delivering care through licensed physicians, nurse practitioners and physician assistants.Source: NavioMD's website; NavioMD's telehealth consent and open payments notice.
S2PASSThe eligibility button opens a health intake whose first screen introduces questions on goals, lifestyle and health history, and the product pages say medication ships only after the patient is approved.Source: NavioMD's tirzepatide b6 page on its app site; NavioMD's compounded tirzepatide product page.
S3PASSEvery prescription is dispensed through The Pharmacy Hub, named in the answers, on the about page, in the terms and in the telehealth consent as the exclusive fulfillment partner and a 503A pharmacy licensed to ship to all 50 states. No city or state is printed beside the name.Source: NavioMD's website; NavioMD's about us page; NavioMD's telehealth consent and open payments notice.
S4FAILThe sermorelin and glutathione pages carry no statement that the product is compounded or that it is not FDA-approved. The tirzepatide and NAD+ pages carry the statement, but the pages selling sermorelin and glutathione do not.Source: NavioMD's sermorelin product page; NavioMD's glutathione product page; NavioMD's compounded tirzepatide product page.
S5FAILNo certificate of analysis or lot document is published on the product pages, the answers, the terms or the privacy policy.Source: NavioMD's compounded tirzepatide product page; NavioMD's terms of service page.
S6PASSNavioMD, Inc. at 7901 4th St N #23153, St. Petersburg, FL 33702, printed in the footer of every page, in the terms and in the privacy policy.Source: NavioMD's website; NavioMD's terms of service page; NavioMD's privacy policy.
S7PASSCompounded tirzepatide at $189 a month at the 2.5 mg to 7.5 mg doses and $209 at the 10 mg to 15 mg doses, the $189 shown against a struck-through $299. Brand Zepbound from $445 a month. Sermorelin at $135, NAD+ at $145 and glutathione at $125, progesterone capsules from $75 a month and Biest from $92 a month. An optional support plan costs $75 a month.Source: NavioMD's compounded tirzepatide product page; NavioMD's zepbound r product page; NavioMD's sermorelin product page; NavioMD's NAD+ product page.
S8PASSNo FDA warning letter names NavioMD or NavioMD, Inc., and no action has halted the business.Source: FDA warning-letter index.
Products shown on the seller's own pages at the recorded date: compounded tirzepatide, brand Zepbound KwikPen, sermorelin, NAD+ injection, glutathione injection, Biest, progesterone capsules.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.